Penny Stock To Watch: Inhibitex, Inc. (NASDAQ:INHX)
Inhibitex, Inc., a biopharmaceutical company, focuses on the development of differentiated anti-infective products to prevent or treat serious infections, primarily shingles and chronic infections caused by hepatitis C virus (HCV). Its antiviral product candidates include FV-100, an orally available nucleoside analogue prodrug, which is in Phase II trials for the treatment of herpes zoster or shingles; and INX-189, a HCV nucleoside polymerase inhibitor that has completed preclinical studies for the treatment of chronic hepatitis C infection.
INHX is also developing anti-bacterials, including Staphylococcal Vaccine, which is in Phase I trial to prevent S. aureus infections; and Aurexis, a humanized monoclonal antibody that has completed Phase II trials for the treatment of S. aureus bloodstream infections in hospitalized patients. It has a license and collaboration agreement with Wyeth Pharmaceuticals for the development of active vaccines against staphylococcus from MSCRAMM protein platform.
Inhibitex, Inc. was upgraded by Deutsche Bank Thursday to a “Buy” rating.
Inhibitex, Inc. closed Thursday at $3.96Share